The founder of XPD Consulting, Dr. Andrew Parkinson, has over 25 years of academic experience and over 16 years of industrial experience in the area of in vitro drug metabolism and safety testing

Dr. Andrew Parkinson was a full-time faculty member at the University of Kansas Medical Center from 1987 to 1999. Since 1999 he has held an adjunct professorship of pharmacology and toxicology at KUMC

Dr. Andrew Parkinson founded XenoTech, a contract research organization specializing in in vitro drug metabolism and safety testing. He served as CEO and/or CSO until 2011

Dr. Andrew Parkinson has consulted for over 100 pharmaceutical clients and written over 75 Expert Opinions for clients in North America, Europe and Japan

Brandy Paris worked for XenoTech from 1998 to 2011. Her positions included Head of Drug Inhibition, Executive Consultant and Chief Operating Officer

Dr. Oliver Parkinson worked for XenoTech and for Dr. Elizabeth Gillam at the University of Queensland, Australia before he entered graduate school at the University of Washington in Seattle, where his Ph.D. advisor was Professor Allan Rettie

Today, at XPD Consulting, Dr. Andrew Parkinson serves as CEO, Brandy Paris as President, and Dr. Oliver Parkinson as Consultant.